Literature DB >> 23042345

A complex substitute: antibody therapy for hemophilia.

David Lillicrap.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23042345     DOI： 10.1038/nm.2959

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  11 in total

Review 1.  Activation of factor VIII and mechanisms of cofactor action.

Authors:  Philip J Fay
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

2.  Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

Authors:  I M Nilsson; E Berntorp; T Löfqvist; H Pettersson
Journal:  J Intern Med       Date:  1992-07       Impact factor: 8.989

Review 3.  Prediction of immunogenicity for therapeutic proteins: state of the art.

Authors:  Anne S De Groot; Leonard Moise
Journal:  Curr Opin Drug Discov Devel       Date:  2007-05

4.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

5.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

Authors:  Jan Astermark; Sharyne M Donfield; Donna M DiMichele; Alessandro Gringeri; Steven A Gilbert; Jennifer Waters; Erik Berntorp
Journal:  Blood       Date:  2006-09-21       Impact factor: 22.113

6.  Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Authors:  Baisong Mei; Clark Pan; Haiyan Jiang; Hendri Tjandra; Jonathan Strauss; Yaoqi Chen; Tongyao Liu; Xin Zhang; Joanne Severs; Jim Newgren; Jianmin Chen; Jian-Ming Gu; Babu Subramanyam; Michael A Fournel; Glenn F Pierce; John E Murphy
Journal:  Blood       Date:  2010-03-01       Impact factor: 22.113

7.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

8.  Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom.

Authors:  Charles R M Hay; Ben Palmer; Elizabeth Chalmers; Ri Liesner; Rhona Maclean; Savita Rangarajan; Michael Williams; Peter W Collins
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

Review 9.  Haemophilias A and B.

Authors:  Paula H B Bolton-Maggs; K John Pasi
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

10.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.